CD114. also known as the granulocyte-macrophage colony-stimulating factor receptor α subunit (GM-CSFRα or CSF2RA), is a cell surface protein that forms part of the receptor complex for GM-CSF, a cytokine critical for hematopoiesis and immune regulation. The CD114 antibody specifically targets this subunit, enabling researchers to study GM-CSF signaling pathways and receptor expression in various contexts. GM-CSF binding to CD114 triggers dimerization with the β subunit (CD131), activating downstream JAK-STAT, MAPK, and PI3K pathways that regulate myeloid cell proliferation, differentiation, and survival.
CD114 antibodies are widely used in flow cytometry, immunohistochemistry, and Western blotting to analyze receptor distribution and density on hematopoietic cells, including granulocytes, monocytes, and macrophages. These tools have revealed CD114's role in both physiological processes (e.g., infection response) and pathological conditions. Elevated CD114 expression is associated with certain leukemias, autoimmune disorders, and chronic inflammation, making it a potential diagnostic marker or therapeutic target. Neutralizing CD114 antibodies are also explored for blocking GM-CSF signaling in inflammatory diseases like rheumatoid arthritis.
Research applications extend to understanding myeloid cell development, cytokine crosstalk, and receptor trafficking. Commercially available CD114 antibodies vary in clonality (monoclonal/polyclonal), species reactivity, and conjugation formats, requiring validation for specific experimental models. Recent studies also investigate CD114's involvement in tumor microenvironment modulation and immunotherapy resistance.